Medical Device Penetration Testing for NeuroTech & BCIs
Penetration testing for BCIs, neurostimulators, DBS, and closed-loop neuromodulation. Implant RF, programmer trust, and patient-app exposure tested.
Aligned to FDA's February 3, 2026 premarket cybersecurity guidance.
NeuroTechnology devices - BCIs, DBS systems, spinal cord stimulators, closed-loop neuromodulation - pair the regulatory weight of a Class III implant with the consumer-app exposure of a wearable. A compromise of stimulation parameters can affect motor control, mood, or cognition directly. Pen testing for this segment is necessarily a system-of-systems test: implant ↔ clinician programmer, implant ↔ patient remote, programmer ↔ cloud, and the closed-loop path inside the implant itself.
We analyze the wireless link to the implant - typically MICS, BLE, or a proprietary RF profile - for pairing strength, session uniqueness, and whether stimulation-parameter writes are gated by an additional clinician-presence factor. We exercise the clinician programmer (often a hardened tablet) for credential storage, session timeout, and whether a stolen programmer is meaningfully different from a stolen consumer phone (it usually isn't, by default). On the patient side we test the consumer companion app the way an attacker would: rooted device, instrumented runtime, MITM with pinned certs bypassed - looking for whether the implant collapses to trusting the app's view of the world. For closed-loop systems we audit the sensing-to-stimulation control integrity: can a spoofed neural signal drive the actuator, and what's the fail-safe if the sense path is suppressed? Reports are framed as risk-control evidence the regulatory team can take into a Q-Sub conversation.
Brain-computer interfaces (BCIs) add risks that a standard implant test can miss. A BCI records neural signals, often streams them to a phone or the cloud, and may use them to drive stimulation or an external device. We test whether recorded neural data can be read or copied on the implant link, the phone, and the cloud. We test whether decoded output can be spoofed or replayed. We test the inductive charging and telemetry link for unauthenticated commands. We test the firmware update path for implanted hardware that cannot be swapped easily. Every finding is tied back to patient safety first.
Layers we exercise in this engagement
The neurotech / bci system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this medical device penetration testing services.
- 01Cloud APIs Tested
- 02Patient remote Tested
- 03Clinician programmer Tested
- 04BLE / MICS / proprietary RF Tested
- 05Implant firmware Tested
- 06Closed-loop sensing Tested
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Medical Device Penetration Testing Services engagement, end to end
Four phases, fixed fee, scoped to neurotech / bci architecture from kickoff onward.
- 01
Scope + kickoff
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. A written proposal within 24 hours.
- 02
Threat-model alignment
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
- 03
Test execution
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
- 04
Submission-formatted report plus retest
eSTAR-format report with findings, CVSS 4.0 scores, remediation, and retests until every finding with uncontrolled risk is closed.
What we see in NeuroTech / BCI medical device penetration testing services
The patterns we hit in this segment, this service, again and again.
Stimulation parameter writes without a clinician-presence factor
Once paired, a programmer can sometimes change pulse width or amplitude without re-authenticating. We test this path and check whether the stolen-programmer scenario is in the threat model.
Companion app HMAC key shared across a device model
A companion app can embed a single HMAC key used to sign implant commands. We test whether extracting it from one app would allow forged commands to any device of that model.
Closed-loop sense channel without integrity checks
The internal path between sense electrodes and the stim controller can lack an integrity check. We use bench fault injection on the sense ADC to test whether it can drive unintended stimulation.
Neural recordings readable outside the intended clinic
BCI recordings can sync to cloud storage for research or remote review. We test whether access controls, encryption, and tenant separation keep one clinic or study from reading another's neural data.
Decoded BCI output accepted without integrity checks
A BCI can send decoded intent to a cursor, speller, or assistive device. We test whether that output can be injected or replayed between the implant, the processor, and the controlled device.
Cloud device registry enumeration across clinics
We test whether an authenticated clinician account can list devices outside its assigned clinic through predictable enumeration on the registry endpoint.
Public neurotech / bci cybersecurity history
Recalls, CISA ICS-MA advisories, and disclosed research that shape what reviewers ask about in this segment - and what our scope is built to cover.
- CISA + FDA·2018
Medtronic N'Vision clinician programmer (CISA ICSMA-18-137-01, 2018)
Physical access to the programmer's therapy application card could expose patient data or allow arbitrary code to run on the programmer.
Advisory - CISA + FDA·2023
Medtronic Micro Clinician and InterStim X apps (CISA ICSMA-23-061-01, 2023)
An unverified password change could reset the clinician app's custom password to the default.
Advisory
NeuroTech / BCI reading and listening
- Device areaNeuroTechnology & Brain-Computer Interfaces cybersecurity
- ServiceThreat Modeling for NeuroTech & BCIs
- ServiceFDA Postmarket Cybersecurity for NeuroTech & BCIs
- ArticleBrainjacking: Neurotech Cybersecurity Risks and FDA Rules
- ArticleMedical Device Cybersecurity From Animal Studies to Human Trials
- ArticleQ-Day: A Present-Day FDA Compliance Gap
- PodcastFrom Science Fiction to Visual Prosthesis with Frederik Ceyssens
- PodcastScience Before Hype in MedTech Investing with Varun Turlapati of Chaanakya Capital
"Blue Goat's niche expertise in FDA-facing cybersecurity made all the difference. Their reports were built with the FDA's expectations in mind; it gave us confidence that we were submitting exactly what reviewers want to see."
Standard Medical Device Penetration Testing Services deliverables
The same deliverables the parent Medical Device Penetration Testing Services service ships with - tuned to your neurotech / bci architecture.
- Device, firmware, and embedded testing: hardware teardown, JTAG/UART/SPI bus access, firmware extraction and reverse engineering, and exploitation of the secure boot, debug, and update paths. Done by operators who have tested infusion pumps, monitors, surgical robots, and implantables.
- Companion app and cloud API coverage: iOS/Android binary analysis, BLE pairing/GATT attacks, REST/MQTT/gRPC fuzzing, authentication and authorization testing, and tenant-isolation checks. We test the device as patients and clinicians actually use it, not in isolation.
- penetration test reports structured for FDA premarket submissions: executive summary, methodology, CVSS-scored findings tied to your threat model, reproduction steps, and documented tester independence, scope, methods, and results. Reviewer-ready, not a generic IT security PDF.
- Remediation guidance and re-test included: written fix recommendations per finding, engineer-to-engineer support during remediation, and unlimited retests until every finding with uncontrolled risk is closed, inside the fixed fee. Accepted residual risks remain documented in your risk file.
What lands in your eSTAR submission
Documents structured for the cybersecurity attachments of your submission - no reformatting on your side.
- Device, firmware, and embedded testing: hardware teardown, JTAG/UART/SPI bus access, firmware extraction and reverse engineering, and exploitation of the secure boot, debug, and update paths. Done by operators who have tested infusion pumps, monitors, surgical robots, and implantables.
- Companion app and cloud API coverage: iOS/Android binary analysis, BLE pairing/GATT attacks, REST/MQTT/gRPC fuzzing, authentication and authorization testing, and tenant-isolation checks. We test the device as patients and clinicians actually use it, not in isolation.
- penetration test reports structured for FDA premarket submissions: executive summary, methodology, CVSS-scored findings tied to your threat model, reproduction steps, and documented tester independence, scope, methods, and results. Reviewer-ready, not a generic IT security PDF.
- Remediation guidance and re-test included: written fix recommendations per finding, engineer-to-engineer support during remediation, and unlimited retests until every finding with uncontrolled risk is closed, inside the fixed fee. Accepted residual risks remain documented in your risk file.
Standards that apply
The NeuroTech / BCI baseline, plus the call-outs that matter for medical device penetration testing services in this segment.
Segment-specific call-outs
IEC 60601-2-10 (nerve and muscle stimulators) + ANSI/AAMI SW96
Cyber findings on stim parameters are essential-performance impacts. Risk-control treatment must reflect that, not be relegated to annex IT considerations.
AAMI TIR97 (postmarket security risk management for device manufacturers)
Implants stay in patients for years, which makes the postmarket plan part of the premarket package. We test what's deployed AND what the update path looks like.
What's not in scope
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
- Hospital enterprise IT network penetration testing
- Clinical efficacy or human-factors validation
- Physical security of manufacturing sites
- Source-code review (unless explicitly added as a separate engagement)
Medical Device Penetration Testing Services for NeuroTech / BCI - FAQs
The questions buyers in this segment actually ask before scoping a medical device penetration testing services engagement.
Go deeper on NeuroTech / BCI and premarket
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
The most common high- and critical-severity findings we surface in medical device penetration tests, what each one looks like in the field, and how to fix it before your FDA submission.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
Medical device cybersecurity should scale with device risk. Christian Espinosa argues why meeting only the Section 524B minimum leaves patients and submissions exposed.
VEX resources for medical device teams: a document guide, SBOM comparison, and common assessment mistakes, with evidence-based status and regulatory context.
Medical device cybersecurity for nanotech neurostimulation: a fictional STRIDE threat model linking controller risks, patient harms, controls, and testing.
Other engagements for NeuroTech / BCI
Teams in this segment commonly bundle these alongside medical device penetration testing services.
Keep going
Scope a Medical Device Penetration Testing Services engagement for your neurotech / bci program.
A 30-minute discovery call with Christian Espinosa, Founder and CEO, and Kristy Kennedy, VP of Sales. Blue Goat has done neurotech and BCI engagements before.